FindTrial
Sign In

Effect of a unani formulation in the treatment of Shara (hives)

Scientific evaluation for the effect of a unani Pharmacopoeial compound NUQU-E-UNNAB in Shara (Urticaria)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/10/046562
Enrollment
60
Registered
2022-10-17
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L509- Urticaria, unspecified

Interventions

Intervention1: UNANI PHARMACOPOEAL PREPARATION : Unnab-Zizyphus sativa-7 Fruit Aloo Bukhara-Prunus domestica 4 Fruit Kishneez-Coriandrum sativum- Fruit-7 gm Shahtra-Fumaria officinalis-Whole plant- 8

Sponsors

Department of Ilmul Advia
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Clinically diagnosed patients of CU according to the 2018 EAACI/GA2LEN/EDF/WAO guideline 2. Patients willing to sign consent form for the study.

Exclusion criteria

Exclusion criteria: 1. Patients less than 14 and more than 60 years of age. 2. concomitant skin disease. 3. Patients suffering from any other systemic diseases, pregnant and lactating women. 4. unwillingness or inability to fulfil the protocol.

Design outcomes

Primary

MeasureTime frame
DECLINE IN WHEALS EPISODES AND ITCHING INTENSITYTimepoint: EVERY FORTNIGHT UPTO 6 WEEKS—

Secondary

MeasureTime frame
IMPROVEMENT IN OBJECTIVE PARAMETERS LIKE QoL QUESTIONNAIRE, UAS7 AND BLOOD REPORTSTimepoint: BEFORE AND AFTER STUDY—

Countries

India

Contacts

Public ContactUzma Khatoon

Ajmal Khan Tibbiya College, AMU, Aligarh

abdurraufmd@yahoo.com9457357442

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026